{"pmid":32380475,"title":"Endocrinology in the time of COVID-19: Management of Cushing's syndrome.","text":["Endocrinology in the time of COVID-19: Management of Cushing's syndrome.","* Clinical evaluation should guide those needing investigation * Strict adherence to COVID-19 protection measures is necessary * Alternative ways of consultations (telephone, video) should be used * Early discussion with regional/national experts about investigation and management of potential and existing patients is strongly encouraged * Patients with moderate and severe clinical features need urgent investigation and management * Patients with active Cushing's syndrome, especially when severe, are immunocompromised and social shielding is recommended * In patients with mild features or in whom a diagnosis is less likely, clinical re-evaluation should be repeated at three and six months or deferred until the prevalence of SARS-CoV-2 has significantly decreased * Diagnostic pathways may need to be very different from usual recommendations in order to reduce investigations * When extensive differential diagnostic testing is not feasible, it should be deferred, and medical treatment should be initiated * Transsphenoidal pituitary surgery may be avoided during high SARS-CoV-2 viral prevalence * Medical management rather than surgery will be the used for most patients since the short- to mid-term prognosis depends in most cases on hypercortisolism rather than its cause; it should be initiated promptly to minimize the risk of infection in these immunosuppressed patients.","Eur J Endocrinol","Newell-Price, John","Nieman, Lynnette","Reincke, Martin","Tabarin, A","32380475"],"abstract":["* Clinical evaluation should guide those needing investigation * Strict adherence to COVID-19 protection measures is necessary * Alternative ways of consultations (telephone, video) should be used * Early discussion with regional/national experts about investigation and management of potential and existing patients is strongly encouraged * Patients with moderate and severe clinical features need urgent investigation and management * Patients with active Cushing's syndrome, especially when severe, are immunocompromised and social shielding is recommended * In patients with mild features or in whom a diagnosis is less likely, clinical re-evaluation should be repeated at three and six months or deferred until the prevalence of SARS-CoV-2 has significantly decreased * Diagnostic pathways may need to be very different from usual recommendations in order to reduce investigations * When extensive differential diagnostic testing is not feasible, it should be deferred, and medical treatment should be initiated * Transsphenoidal pituitary surgery may be avoided during high SARS-CoV-2 viral prevalence * Medical management rather than surgery will be the used for most patients since the short- to mid-term prognosis depends in most cases on hypercortisolism rather than its cause; it should be initiated promptly to minimize the risk of infection in these immunosuppressed patients."],"journal":"Eur J Endocrinol","authors":["Newell-Price, John","Nieman, Lynnette","Reincke, Martin","Tabarin, A"],"date":"2020-05-08T11:00:00Z","year":2020,"_id":"32380475","source":"PubMed","week":"202019|May 04 - May 10","doi":"10.1530/EJE-20-0352","topics":["Prevention"],"weight":1,"_version_":1666596532356382720,"score":9.490897,"similar":[{"pmid":32438340,"title":"Endocrinology in the time of COVID-19: Management of hyper- and hypo- thyroidism.","text":["Endocrinology in the time of COVID-19: Management of hyper- and hypo- thyroidism.","This manuscript provides guidance on the management of thyroid dysfunction during the COVID-19 pandemic. Auto-immune thyroid diseases are not linked to increased risks of COVID-19. Uncontrolled thyrotoxicosis may result in more severe complications from SARS-CoV-2 infection, including thyroid storm. The management of patients with a new diagnosis of hyperthyroidism is best undertaken with a block and replace regimen due to limited biochemical testing availability. Antithyroid drug (ATD)-induced neutropenia may favour the progression of COVID-19 and symptoms of infection may be confused with SARS-CoV-2 infection. The withdrawal of ATDs and urgent measurement of neutrophils should be considered in case of flu-like manifestations occurring in the initial months of treatment. Urgent surgery or 131-I may be undertaken in selected cases of uncontrolled thyrotoxicosis. Patients with COVID-19 infection may present with conjunctivitis, which could cause diagnostic difficulties in patients with new or existing Graves' ophthalmopathy. Patients who are on replacement treatment with thyroid hormones should ensure they have sufficient supply of medication. The usual advice to increase dosage of levothyroxine during pregnancy should be adhered to. Many newly presenting and previously diagnosed patients with thyroid dysfunction can be managed through virtual telephone or video clinics supported by a dedicated nurse-led service, depending on available facilities.","Eur J Endocrinol","Boelaert, Kristien","Visser, W Edward","Taylor, Peter Nicholas","Moran, Carla","Leger, Juliane","Persani, Luca","32438340"],"abstract":["This manuscript provides guidance on the management of thyroid dysfunction during the COVID-19 pandemic. Auto-immune thyroid diseases are not linked to increased risks of COVID-19. Uncontrolled thyrotoxicosis may result in more severe complications from SARS-CoV-2 infection, including thyroid storm. The management of patients with a new diagnosis of hyperthyroidism is best undertaken with a block and replace regimen due to limited biochemical testing availability. Antithyroid drug (ATD)-induced neutropenia may favour the progression of COVID-19 and symptoms of infection may be confused with SARS-CoV-2 infection. The withdrawal of ATDs and urgent measurement of neutrophils should be considered in case of flu-like manifestations occurring in the initial months of treatment. Urgent surgery or 131-I may be undertaken in selected cases of uncontrolled thyrotoxicosis. Patients with COVID-19 infection may present with conjunctivitis, which could cause diagnostic difficulties in patients with new or existing Graves' ophthalmopathy. Patients who are on replacement treatment with thyroid hormones should ensure they have sufficient supply of medication. The usual advice to increase dosage of levothyroxine during pregnancy should be adhered to. Many newly presenting and previously diagnosed patients with thyroid dysfunction can be managed through virtual telephone or video clinics supported by a dedicated nurse-led service, depending on available facilities."],"journal":"Eur J Endocrinol","authors":["Boelaert, Kristien","Visser, W Edward","Taylor, Peter Nicholas","Moran, Carla","Leger, Juliane","Persani, Luca"],"date":"2020-05-22T11:00:00Z","year":2020,"_id":"32438340","source":"PubMed","week":"202021|May 18 - May 24","doi":"10.1530/EJE-20-0445","locations":["Antithyroid","neutropenia"],"e_drugs":["Thyroxine"],"topics":["Prevention"],"weight":1,"_version_":1667521393592369153,"score":227.65407},{"pmid":32369770,"title":"Endocrinology in the time of COVID-19: Management of pituitary tumours.","text":["Endocrinology in the time of COVID-19: Management of pituitary tumours.","Patients with pituitary tumours, ensuing hormonal abnormalities and mass effects are usually followed in multidisciplinary pituitary clinics and can represent a management challenge even during times of non-pandemic. The COVID-19 pandemic has put on hold routine medical care for hundreds of millions of patients around the globe, while many pituitary patients' evaluations cannot be delayed for too long. Furthermore, the majority of patients with pituitary tumours have co-morbidities potentially impacting the course and management of COVID-19 (e.g. hypopituitarism, diabetes mellitus, hypertension, obesity, cardiovascular disease). Here, we summarize some of the diagnostic and management dilemmas for these patients, and we provide guidance on safe and as effective as possible delivery of care in the COVID-19 era. We also attempt to address how pituitary services should be remodelled in the event of similar crises, while maintaining or even improving patient outcomes. Regular review of these recommendations and further adjustments are needed, depending on the evolution of the COVID-19 pandemic status. We consider that utilization of successful models of pituitary multidisciplinary care implemented during the COVID-19 pandemic should continue after the crisis is over by using the valuable and exceptional experience gained during these challenging times.","Eur J Endocrinol","Fleseriu, Maria","Karavitaki, Niki","Dekkers, Olaf M","32369770"],"abstract":["Patients with pituitary tumours, ensuing hormonal abnormalities and mass effects are usually followed in multidisciplinary pituitary clinics and can represent a management challenge even during times of non-pandemic. The COVID-19 pandemic has put on hold routine medical care for hundreds of millions of patients around the globe, while many pituitary patients' evaluations cannot be delayed for too long. Furthermore, the majority of patients with pituitary tumours have co-morbidities potentially impacting the course and management of COVID-19 (e.g. hypopituitarism, diabetes mellitus, hypertension, obesity, cardiovascular disease). Here, we summarize some of the diagnostic and management dilemmas for these patients, and we provide guidance on safe and as effective as possible delivery of care in the COVID-19 era. We also attempt to address how pituitary services should be remodelled in the event of similar crises, while maintaining or even improving patient outcomes. Regular review of these recommendations and further adjustments are needed, depending on the evolution of the COVID-19 pandemic status. We consider that utilization of successful models of pituitary multidisciplinary care implemented during the COVID-19 pandemic should continue after the crisis is over by using the valuable and exceptional experience gained during these challenging times."],"journal":"Eur J Endocrinol","authors":["Fleseriu, Maria","Karavitaki, Niki","Dekkers, Olaf M"],"date":"2020-05-06T11:00:00Z","year":2020,"_id":"32369770","source":"PubMed","week":"202019|May 04 - May 10","doi":"10.1530/EJE-20-0473","topics":["Prevention"],"weight":1,"_version_":1666138496277938176,"score":210.50734},{"pmid":32445315,"title":"Uro-oncology in times of COVID-19: The available evidence and recommendations in the Indian scenario.","text":["Uro-oncology in times of COVID-19: The available evidence and recommendations in the Indian scenario.","The Corona Virus Disease-2019 (COVID-19), one of the most devastating pandemics ever, has left thousands of cancer patients to their fate. The future course of this pandemic is still an enigma, but health care services are expected to resume soon in a phased manner. This might be a long drawn process and we need to have policies in place, to be able to fight both, the SARS-CoV-2 virus and cancer, simultaneously, and emerge triumphant. An extensive literature search for impact of delay in management of various urological malignancies was carried out. Expert opinions were sought wherever there was paucity of evidence, in order to reach a consensus and come up with recommendations for directing uro-oncology services in the times of COVID-19. The panel recommends deferring treatment of patients with renal cell carcinoma by 3 to 6 months, except for those with ongoing hematuria and/or inferior vena cava thrombus, which warrant immediate surgery. Metastatic renal cell cancers should be started on targeted therapy. Low grade non-muscle invasive bladder cancers can be kept on active surveillance while high risk non-muscle invasive bladder cancers and muscle invasive bladder cancers should be treated within 3 months. Neoadjuvant chemotherapy should be avoided. Management of low and intermediate risk prostate cancer can be deferred for 3 to 6months while high risk prostate cancer patients can be initiated on neoadjuvant androgen deprivation therapy. Patients with testicular tumors should undergo high inguinal orchiectomy and be treated according to stage without delay, with stage I patients being offered surveillance. Penile cancers should undergo penectomy, while clinically negative groins can be kept on surveillance. Neoadjuvant chemotherapy should be avoided and adjuvant therapy should be deferred. We need to tailor our treatment strategies to the prevailing present conditions, so as to fight and defeat both, the SARS-CoV-2 virus and cancer. Protection of health care workers, judicious use of available resources, and a rational and balanced outlook towards different malignancies is the need of the hour.","Indian J Cancer","Narain, Tushar A","Gautam, Gagan","Seth, Amlesh","Panwar, Vikas K","Rawal, Sudhir","Dhar, Puneet","Talwar, Harkirat S","Singh, Amitabh","Jaipuria, Jiten","Mittal, Ankur","32445315"],"abstract":["The Corona Virus Disease-2019 (COVID-19), one of the most devastating pandemics ever, has left thousands of cancer patients to their fate. The future course of this pandemic is still an enigma, but health care services are expected to resume soon in a phased manner. This might be a long drawn process and we need to have policies in place, to be able to fight both, the SARS-CoV-2 virus and cancer, simultaneously, and emerge triumphant. An extensive literature search for impact of delay in management of various urological malignancies was carried out. Expert opinions were sought wherever there was paucity of evidence, in order to reach a consensus and come up with recommendations for directing uro-oncology services in the times of COVID-19. The panel recommends deferring treatment of patients with renal cell carcinoma by 3 to 6 months, except for those with ongoing hematuria and/or inferior vena cava thrombus, which warrant immediate surgery. Metastatic renal cell cancers should be started on targeted therapy. Low grade non-muscle invasive bladder cancers can be kept on active surveillance while high risk non-muscle invasive bladder cancers and muscle invasive bladder cancers should be treated within 3 months. Neoadjuvant chemotherapy should be avoided. Management of low and intermediate risk prostate cancer can be deferred for 3 to 6months while high risk prostate cancer patients can be initiated on neoadjuvant androgen deprivation therapy. Patients with testicular tumors should undergo high inguinal orchiectomy and be treated according to stage without delay, with stage I patients being offered surveillance. Penile cancers should undergo penectomy, while clinically negative groins can be kept on surveillance. Neoadjuvant chemotherapy should be avoided and adjuvant therapy should be deferred. We need to tailor our treatment strategies to the prevailing present conditions, so as to fight and defeat both, the SARS-CoV-2 virus and cancer. Protection of health care workers, judicious use of available resources, and a rational and balanced outlook towards different malignancies is the need of the hour."],"journal":"Indian J Cancer","authors":["Narain, Tushar A","Gautam, Gagan","Seth, Amlesh","Panwar, Vikas K","Rawal, Sudhir","Dhar, Puneet","Talwar, Harkirat S","Singh, Amitabh","Jaipuria, Jiten","Mittal, Ankur"],"date":"2020-05-24T11:00:00Z","year":2020,"_id":"32445315","source":"PubMed","week":"202021|May 18 - May 24","doi":"10.4103/ijc.IJC_356_20","keywords":["bladder cancer","covid-19","cancer","kindey cancer","open surgery","penile cancer","prostate cancer","robotic surgery","testicular tumor","urooncology"],"locations":["Indian"],"countries":["India"],"countries_codes":["IND|India"],"topics":["Prevention"],"weight":1,"_version_":1667600475950678016,"score":188.77022},{"pmid":32355509,"pmcid":"PMC7190476","title":"[Antibiotics alone as an alternative to appendectomy for uncomplicated acute appendicitis in adults: changes in treatment modalities related to the COVID-19 health crisis].","text":["[Antibiotics alone as an alternative to appendectomy for uncomplicated acute appendicitis in adults: changes in treatment modalities related to the COVID-19 health crisis].","The massive inflow of patients with COVID-19 requiring urgent care has overloaded hospitals in France and impacts the management of other patients. Deferring hospitalization and non-urgent surgeries has become a priority for surgeons today in order to relieve the health care system.It is obviously not simple to reduce emergency surgery without altering the quality of care or leading to a loss of chance for the patient. Acute appendicitis is a very specific situation and the prevalence of this disease leads us to reconsider this particular disease in the context of the COVID-19 crisis. Indeed, while the currently recommended treatment for uncomplicated acute appendicitis is surgical appendectomy, the non-surgical alternative of medical management by antibiotic therapy alone has been widely evaluated by high-quality studies in the literature. Insofar as the main limitation of exclusively medical treatment of uncomplicated acute appendicitis is the risk of recurrent appendicitis, this treatment option represents an alternative of choice to reduce the intra-hospital overload in this context of health crisis.The aim of this work is therefore to provide physicians and surgeons with a practical guide based on a review of the literature on the medical treatment of uncomplicated acute appendicitis in adults, to offer this alternative treatment to the right patients and under good conditions, especially when access to the operating room is limited or impossible.","Collard, Maxime","Lefevre, Jeremie H","Maggiori, Leon","32355509"],"abstract":["The massive inflow of patients with COVID-19 requiring urgent care has overloaded hospitals in France and impacts the management of other patients. Deferring hospitalization and non-urgent surgeries has become a priority for surgeons today in order to relieve the health care system.It is obviously not simple to reduce emergency surgery without altering the quality of care or leading to a loss of chance for the patient. Acute appendicitis is a very specific situation and the prevalence of this disease leads us to reconsider this particular disease in the context of the COVID-19 crisis. Indeed, while the currently recommended treatment for uncomplicated acute appendicitis is surgical appendectomy, the non-surgical alternative of medical management by antibiotic therapy alone has been widely evaluated by high-quality studies in the literature. Insofar as the main limitation of exclusively medical treatment of uncomplicated acute appendicitis is the risk of recurrent appendicitis, this treatment option represents an alternative of choice to reduce the intra-hospital overload in this context of health crisis.The aim of this work is therefore to provide physicians and surgeons with a practical guide based on a review of the literature on the medical treatment of uncomplicated acute appendicitis in adults, to offer this alternative treatment to the right patients and under good conditions, especially when access to the operating room is limited or impossible."],"authors":["Collard, Maxime","Lefevre, Jeremie H","Maggiori, Leon"],"date":"2020-05-02T11:00:00Z","year":2020,"_id":"32355509","source":"PubMed","week":"202018|Apr 27 - May 03","doi":"10.1016/j.jchirv.2020.04.014","keywords":["covid-19","acute appendicitis","antibiotic therapy","appendectomy","coronavirus"],"locations":["France"],"countries":["France"],"countries_codes":["FRA|France"],"topics":["Prevention"],"weight":1,"_version_":1666138495266062336,"score":185.71637},{"pmid":32362368,"pmcid":"PMC7181971","title":"Antibiotics alone as an alternative to appendectomy for uncomplicated acute appendicitis in adults: Changes in treatment modalities related to the COVID-19 health crisis.","text":["Antibiotics alone as an alternative to appendectomy for uncomplicated acute appendicitis in adults: Changes in treatment modalities related to the COVID-19 health crisis.","The massive inflow of patients with COVID-19 requiring urgent care has overloaded hospitals in France and impacts the management of other patients. Deferring hospitalization and non-urgent surgeries has become a priority for surgeons today in order to relieve the health care system. It is obviously not simple to reduce emergency surgery without altering the quality of care or leading to a loss of chance for the patient. Acute appendicitis is a very specific situation and the prevalence of this disease leads us to reconsider this particular disease in the context of the COVID-19 crisis. Indeed, while the currently recommended treatment for uncomplicated acute appendicitis is surgical appendectomy, the non-surgical alternative of medical management by antibiotic therapy alone has been widely evaluated by high-quality studies in the literature. Insofar as the main limitation of exclusively medical treatment of uncomplicated acute appendicitis is the risk of recurrent appendicitis, this treatment option represents an alternative of choice to reduce the intra-hospital overload in this context of health crisis. The aim of this work is therefore to provide physicians and surgeons with a practical guide based on a review of the literature on the medical treatment of uncomplicated acute appendicitis in adults, to offer this alternative treatment to the right patients and under good conditions, especially when access to the operating room is limited or impossible.","J Visc Surg","Collard, M","Lakkis, Z","Loriau, J","Mege, D","Sabbagh, C","Lefevre, J H","Maggiori, L","32362368"],"abstract":["The massive inflow of patients with COVID-19 requiring urgent care has overloaded hospitals in France and impacts the management of other patients. Deferring hospitalization and non-urgent surgeries has become a priority for surgeons today in order to relieve the health care system. It is obviously not simple to reduce emergency surgery without altering the quality of care or leading to a loss of chance for the patient. Acute appendicitis is a very specific situation and the prevalence of this disease leads us to reconsider this particular disease in the context of the COVID-19 crisis. Indeed, while the currently recommended treatment for uncomplicated acute appendicitis is surgical appendectomy, the non-surgical alternative of medical management by antibiotic therapy alone has been widely evaluated by high-quality studies in the literature. Insofar as the main limitation of exclusively medical treatment of uncomplicated acute appendicitis is the risk of recurrent appendicitis, this treatment option represents an alternative of choice to reduce the intra-hospital overload in this context of health crisis. The aim of this work is therefore to provide physicians and surgeons with a practical guide based on a review of the literature on the medical treatment of uncomplicated acute appendicitis in adults, to offer this alternative treatment to the right patients and under good conditions, especially when access to the operating room is limited or impossible."],"journal":"J Visc Surg","authors":["Collard, M","Lakkis, Z","Loriau, J","Mege, D","Sabbagh, C","Lefevre, J H","Maggiori, L"],"date":"2020-05-05T11:00:00Z","year":2020,"_id":"32362368","source":"PubMed","week":"202019|May 04 - May 10","doi":"10.1016/j.jviscsurg.2020.04.014","keywords":["acute appendicitis","antibiotic therapy","appendectomy","covid-19","coronavirus"],"locations":["France"],"countries":["France"],"countries_codes":["FRA|France"],"topics":["Prevention"],"weight":1,"_version_":1666138496093388800,"score":185.71637}]}